November 22, 2024

The Honorable Patty Murray Chair Senate Appropriations Committee S-128, The Capitol Washington, DC 20510

The Honorable Tom Cole Chair House Appropriations Committee H-307, The Capitol Washington, DC 20515 The Honorable Susan Collins Ranking Member Senate Appropriations Committee S-128, The Capitol Washington, DC 20510

The Honorable Rosa DeLauro
Ranking Member
House Appropriations Committee
1036 Longworth House Office Building
Washington, DC 20515

Subject: Laboratory developed tests regulation and the future of patient care

Dear Chair Murray, Ranking Member Collins, Chair Cole, and Ranking Member DeLauro:

The undersigned organizations, who represent a diverse and broad community of patient advocates, laboratory professionals, public health laboratories, clinical laboratories, and more from throughout the United States, are writing to express our strong support for appropriations report language addressing the U.S. Food and Drug Administration's (FDA) final rule on laboratory-developed tests (LDTs). This rule marks a significant shift in how LDTs are regulated, with far-reaching impacts on patients, healthcare providers, and laboratories. We commend the House Appropriations Committee for directing the FDA to pause its implementation of this rule and to collaborate with Congress on modernizing the regulatory approach for LDTs. We urge you to retain this language throughout the FY 2025 appropriations process.

LDTs are vital tools developed and utilized by hospitals, academic institutions, public health, and clinical laboratories to diagnose, monitor, and treat conditions, including cancers, rare diseases, inherited disorders, and infectious diseases. They enable laboratory professionals to assess disease risk, tailor treatment plans, predict drug responses, and provide prognoses. Currently, there are hundreds of thousands of LDTs available for clinical care that successfully guide the decisions of healthcare providers and patients because there are robust federal, state, and third-party mechanisms to ensure their quality. While LDTs are an essential part of the care that laboratory professionals provide to patients and are deeply ingrained in medicine guiding many health care decisions, they differ drastically from boxed and shipped, commercially-sold medical devices, like imaging machines, implantables, and surgical equipment, making the FDA's use of the medical device regulations inappropriate for this field.

The FDA's new rule presents serious concerns for patient care and innovation. According to FDA estimates, over 90% of affected laboratories are small businesses, with average annual receipts of roughly \$4 million—comparable to the cost of a single premarket review submission. This financial burden could force laboratories to prioritize economic viability over patient care, undermining the ability to quickly adapt testing methods to the latest scientific advances. This is not the future we envision for a field so crucial to medical care, disease screening, and response to infectious disease outbreaks.

We stand united in urging Congress to develop a tailored, common-sense approach to regulating laboratories and their testing services. Years of discussion and substantial efforts have been devoted to this issue, aiming for a balanced solution. While our organizations may have varying perspectives, we share a deep concern that the FDA's rule is not the right path forward as it threatens the stability of the laboratory sector and its workforce. Therefore, we strongly urge you to protect the language instructing the FDA to pause its regulatory efforts and to allow Congress, in collaboration with the laboratory community, to craft a modernized framework that fosters innovation and supports patient care.

Sincerely,

Academic Coalition for Effective Laboratory Tests

Academy of Clinical Laboratory Physicians and Scientists

Accu Reference Medical Laboratory

Adela, Inc.

Advanced Genetics Laboratory

Akron Children's Hospital

America's Blood Centers

American College of Medical Genetics and Genomics

American Red Cross

American Society for Clinical Pathology

American Society of Hematology

Appalachian Labs of WV

Arbelos Genomics

ARUP Laboratories

Association for Academic Pathology

Association for Diagnostics & Laboratory Medicine

Association for Molecular Pathology

Association for the Advancement of Blood and Biotherapies (AABB)

Baylor College of Medicine

Biomeck

Boston Consulting

Cedars-Sinai

Children's National Hospital

Choice Pain and Rehabilitation Laboratory

Choice Vending, LLC.

City of Hope

Clinical Immunology Laboratory

Clinical Immunology Society (CIS)

Complete Diagnostic Laboratories, LLC

Concord Life Sciences

Copper State Lab Services

Damajha Systems

DASH Lab Services

Emplify Health Inc.

Flow Health Laboratories LLC

Gemelli Biotech Corp

Genome Medical, Inc

Genomind, Inc

Golden Health Consulting LLC

Greenwood Genetic Center

Helix, Inc.

Hyperdrive Bio

IMMYLabs

Immune Deficiency Foundation

IVD Logix LLC

Kaiser Permanente

Kindlabs llc

KSL Diagnostics Inc.

Lab Voice Media

Leukodystrophy Newborn Screening Action Network

Lifetime Sciences

Lighthouse Lab Services

Lights Right Laboratories

MCDXI Medical Diagnostics, Inc.

MD Labs Clinical Toxicology and Pharmacogenetics

Medical University of South Carolina

Meridian Diagnostics

Minomic Inc

MLD Foundation

Molecupath Consultants, LLC

MSACL

nuCARE Medical Solutions, Inc

Phoenix Laboratory Consulting

Previse

Principle Health System

Project Santa Fe Foundation-Lab 2.0

Promus Diagnostics LLC

Reya Laboratories

RGEN Inc.

Seattle Children's Hospital

Shadowbox, Inc.

Survivors Cancer Action Network

Telos PGX

Tharalink Technologies, Inc.

Three Rivers Diagnostics

TranSoar

Triangle Molecular Toxicology LLC

TriCore Reference Laboratories

Turnkey Clinical Laboratory Consulting

UMASS Memorial Health

University of Rochester

Wake Diagnostics Inc

Weill Cornell Medicine

Z2 Scientific LLC